Visen Pharmaceuticals Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
102
- Stock Symbol
-
02561
- Share Price
-
$1.54
- (As of Tuesday Closing)
Visen Pharmaceuticals General Information
Description
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
Contact Information
Website
www.visenpharma.comCorporate Office
- Room 2501, 1788 International Building
- 1788 Nanjing West Road, Jing'an District
- Shanghai
- China
Corporate Office
- Room 2501, 1788 International Building
- 1788 Nanjing West Road, Jing'an District
- Shanghai
- China
Visen Pharmaceuticals Stock Performance
As of 17-Nov-2026, Visen Pharmaceuticals’s stock price is $1.54. Its current market cap is $168M with 109M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.54 | $1.60 | $1.39 - $5.55 | $168M | 109M | 9.9K | -$0.32 |
Visen Pharmaceuticals Financials Summary
As of 30-Jun-2026, Visen Pharmaceuticals has a trailing 12-month revenue of $4.96M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 225,233 | 329,510 | ||
| Revenue | 4,960 | 23 | 0 | 0 |
| EBITDA | (34,902) | (36,285) | (25,697) | (35,817) |
| Net Income | (34,228) | (35,240) | (25,398) | (35,276) |
| Total Assets | 130,574 | 139,680 | 40,249 | 62,607 |
| Total Debt | 26,008 | 25,296 | 323 | 515 |
Visen Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Visen Pharmaceuticals Comparisons
Industry
Financing
Details
Visen Pharmaceuticals Competitors (1)
One of Visen Pharmaceuticals’s competitors is GeneScience Pharmaceuticals Co., a Corporate Backed or Acquired company based in Changchun, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GeneScience Pharmaceuticals Co. | Corporate Backed or Acquired | Changchun, China |
Visen Pharmaceuticals Patents
Visen Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026021075-A1 | Freeze-drying method for pharmaceuticals, cosmetics or medical beauty products, freeze-dried formulation and injection | Pending | 26-Jul-2024 | ||
| WO-2026021076-A1 | Lyophilization method for lonapegsomatropin, lyophilized formulation of lonapegsomatropin, and injection | Pending | 26-Jul-2024 | ||
| WO-2026021074-A1 | Vial cap assembly | Pending | 26-Jul-2024 | B65D41/28 |
Visen Pharmaceuticals Signals
Visen Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Visen Pharmaceuticals FAQs
-
When was Visen Pharmaceuticals founded?
Visen Pharmaceuticals was founded in 2018.
-
Where is Visen Pharmaceuticals headquartered?
Visen Pharmaceuticals is headquartered in Shanghai, China.
-
What is the size of Visen Pharmaceuticals?
Visen Pharmaceuticals has 102 total employees.
-
What industry is Visen Pharmaceuticals in?
Visen Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Visen Pharmaceuticals a private or public company?
Visen Pharmaceuticals is a Public company.
-
What is Visen Pharmaceuticals’s stock symbol?
The ticker symbol for Visen Pharmaceuticals is 02561.
-
What is the current stock price of Visen Pharmaceuticals?
As of 17-Nov-2026 the stock price of Visen Pharmaceuticals is $1.54.
-
What is the current market cap of Visen Pharmaceuticals?
The current market capitalization of Visen Pharmaceuticals is $168M.
-
What is Visen Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Visen Pharmaceuticals is $4.96M.
-
Who are Visen Pharmaceuticals’s competitors?
GeneScience Pharmaceuticals Co. is a competitor of Visen Pharmaceuticals.
-
What is Visen Pharmaceuticals’s annual earnings per share (EPS)?
Visen Pharmaceuticals’s EPS for 12 months was -$0.32.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process